OM
AEGR

Opaleye Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Opaleye Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-57,500
Closed -$1.92M – 40
2014
Q3 		$1.92M Buy
+57,500
New +$1.78M 1.5% 21

Other funds holding AEGR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Opaleye Management's AEGR Position: Q4 2014 in Review

Opaleye Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 57,500 shares — an estimated $1.92M sold.

Opaleye Management first reported a position in AEGR in Q3 2014 and held it in 1 quarter. The position peaked at $1.92M in Q3 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Opaleye Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Opaleye Management sold 57,500 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $1.92M.
  • Opaleye Management first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Opaleye Management's Aegerion Pharmaceuticals position peaked at $1.92M in Q3 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Opaleye Management's 13F filing for Q4 2014, filed 13 Feb 2015.